

## Synthesis of oligonucleoside phosphorodithioates by the *H*-phosphonothioate method

Kazuo Kamaike,\* Kumi Hirose, Yoshihiro Kayama and Etsuko Kawashima


<sup>a</sup>Laboratory of Pharmaceutical Chemistry, School of Pharmacy, Tokyo University of Pharmacy and Life Science, 1432-1 Horinouchi, Hachioji, Tokyo 192-0392, Japan

Received 18 March 2004; revised 2 June 2004; accepted 4 June 2004

**Abstract**—The phosphorodithioate octamer [(TpS<sub>2</sub>)<sub>7</sub>T] was efficiently synthesized using bis(2,6-dimethylphenyl) phosphorochloridate as a coupling agent by application of the *H*-phosphonothioate method, where oxidation was facilitated using elemental sulfur following completion of oligonucleoside *H*-phosphonothioates assembly, as with the standard *H*-phosphonate method.  
© 2004 Elsevier Ltd. All rights reserved.

Oligonucleoside phosphorodithioates have proven useful as antisense probes.<sup>1–4</sup> Several approaches to the synthesis of these analogues involving the use of phosphorodithioate,<sup>1a,b,d,5</sup> thiophosphoramidite<sup>1d,2a,c,5b,6</sup> *H*-phosphonothioate,<sup>1d,5b,7</sup> *H*-phosphonodithioate,<sup>3,8</sup> phos-

phorodithioate<sup>2b,9</sup> or dithiophospholane<sup>10</sup> monomers have been reported. The *H*-phosphonothioate method (Scheme 1) has advantages in that the *H*-phosphonothioate monomers are stable to hydrolysis and oxidation, the cycle time is short, and there is the possibility of



**Scheme 1.** Reaction cycle for assembly of oligonucleoside phosphorodithioates. Reagents and conditions: (a) 3%  $\text{CCl}_3\text{COOH}/\text{CH}_2\text{Cl}_2$ , 1 min (for deprotection of the DMTr group) or (i) 0.5 M  $\text{NH}_2\text{NH}_2 \cdot \text{H}_2\text{O}$ , 1:4  $\text{CH}_3\text{COOH}/\text{pyridine}$ , 15 min, (ii) 0.5 M imidazole,  $\text{CH}_3\text{CN}$ , 5 min (for deprotection of the LMNBz group); (b) 0.05 M **3**, 0.15–0.25 M coupling agent, 1:4 pyridine/ $\text{CH}_3\text{CN}$ , 10 min; (c) 0.3 M  $\text{S}_8$ , 1:9 2,6-lutidine/ $\text{CH}_2\text{Cl}_2$ , 1 h; (d) 1:1 concd  $\text{NH}_4\text{OH}/\text{EtOH}$ , rt, 3 h–55 °C, 5 h.

**Keywords:** Antisense oligonucleotide; Oligonucleoside phosphorodithioates; *H*-Phosphonothioate method.

\* Corresponding author. Tel.: +81-426-76-3078; fax: +81-426-76-3073; e-mail: kamaikek@ps.toyaku.ac.jp


oxidation without using elemental sulfur in every cycle but only at the end of the synthesis, just as in the standard *H*-phosphonate method. The central issue for oligonucleoside phosphorodithioates synthesis by the *H*-phosphonothioate method involves the selective *O*-activation (**4**) of the *H*-phosphonothioate **3** by a coupling agent. Stawinski and co-workers reported studies on the synthesis of deoxynucleoside *H*-phosphonothioates **3** ( $R = \text{DMTr}$ ) and their use in the synthesis of dinucleoside *H*-phosphonothioates.<sup>7a,b,11</sup> In a study pertaining to the synthesis of dinucleoside *H*-phosphonothioates they reported <sup>31</sup>P NMR studies on the coupling reactions using nucleoside *H*-phosphonothioates with a variety of activators. When diphenyl phosphorochloridate (DPCP) or diethyl phosphorochloridate (DECP) were used as coupling agents, the *H*-phosphonothioate monomers could be selectively activated at the oxygen and coupled. In reactions when more than an equimolar amount of a hydroxylic component was used, some 5'-phosphorylation of the nucleoside by DPCP was observed. On the other hand, side products which may have been generated from the subsequent reaction of oligonucleoside *H*-phosphonothioate with coupling agents (phosphite triester or hypophosphates) were not observed. Caruthers and co-workers developed a new method for the synthesis of oligonucleoside phosphonothioates using *H*-phosphonothioates **3** ( $R = \text{DMTr}$ ).<sup>7e,f</sup> They reported that oxidation with elemental sulfur at the end of the synthesis, just as in the standard *H*-phosphonate method, gave rise to the formation of significant amounts of desulfurized products. The synthesis of oligodeoxynucleoside phosphorodithioates was accomplished by using DPCP as a coupling agent and incorporating an oxidation step using 2,4-dichlorobenzyl thiosuccinimide in each coupling cycle.

On the other hand, we reported on the synthesis of oligonucleoside phosphorodithioates using nucleoside 3'-*H*-phosphonothioates **3** ( $R = \text{LMNBz}$ ) by the standard *H*-phosphonate method, where oxidation was achieved using elemental sulfur following the completion of oligonucleoside *H*-phosphonothioates assembly.<sup>12,13</sup> The trimer ( $\text{TpS}_2\text{TpS}_2\text{T}$ ) was efficiently synthesized using DECP as a coupling agent.<sup>13</sup> The successful synthesis of  $\text{TpS}_2\text{TpS}_2\text{T}$  prompted us to further investigate the utility of this method. We report here further investigations on the synthesis of oligonu-


cleoside phosphorodithioates by the *H*-phosphonothioate method through oxidation using elemental sulfur at the end of the synthesis.

Based on the aforementioned reports,<sup>7a,b,e,f,11,13</sup> the reaction of *H*-phosphonothioate **3** with hydroxylic component **2** using the bulky phosphorochloridate derivative as a coupling agent could be expected to be selectively activated at oxygen and coupled without side reactions, that is the generation of phosphorothioate oligomers and the 5'-phosphorylation of nucleotide by a coupling agent. Additionally, using bulky diphenylphosphorochloridate derivatives having substituents on the phenyl groups as a coupling agent, it was expected that the selectivity relating to *O*-activation (**4**) of the phosphonothioate **3** by a coupling agent could be improved by the electronic effect of substituents on the phenyl groups. The commercially available bis(2,4-dichlorophenyl) phosphorochloridate [(DCP)<sub>2</sub>CP] and bis(2,6-dimethylphenyl) phosphorochloridate [(DMP)<sub>2</sub>CP] were considered as candidates for the effective coupling agent.

At first, a comparative study was performed of the various coupling agents, pivaloyl chloride (PivCl), DPCP, DECP, (DCP)<sub>2</sub>CP, and (DMP)<sub>2</sub>CP. These were employed in the synthesis of oligonucleoside phosphorodithioates as exemplified by the synthesis of dimer  $\text{TpS}_2\text{T}$  using 5'-*O*-DMTr-thymidine 3'-*H*-phosphonothioate **3**<sup>7a,b</sup> on CPG support **1** ( $R = \text{DMTr}$ ) through oxidation using elemental sulfur as shown in Scheme 1 by manual synthesis.<sup>14</sup> Following deprotection of the DMTr group of 5'-*O*-DMTr-thymidine linked to CPG support **1**, *H*-phosphonothioate **3** ( $R = \text{DMTr}$ ) was coupled to thymidine (**2**) in the presence of either PivCl, DPCP, DECP, (DCP)<sub>2</sub>CP, or (DMP)<sub>2</sub>CP. Following *H*-phosphonothioate dimer **5** assembly and subsequent removal of the DMTr group, oxidation was performed using a 0.3 M solution of elemental sulfur in 1:9 2,6-lutidine/dichloromethane for 1 h to yield the desired phosphonodithioate dimer, cleavage of  $\text{TpS}_2\text{T}$  from the support, and analysis by reversed-phase HPLC. The effectiveness of (DMP)<sub>2</sub>CP can clearly be seen from the HPLC profiles shown in Figure 1. Given the low reactivity of the *S*-nucleophile toward the phosphorus center,<sup>7b</sup> the decrease in reactivity of the diphenylphosphorochloridate derivative, due to the effect of the



**Figure 1.** Reversed-phase HPLC profiles of crude products of  $\text{TpS}_2\text{T}$  preparations using the 5'-*O*-DMTr-thymidine *H*-phosphonothioate **3** on CPG **1** ( $R = \text{DMTr}$ ) in the presence of Piv-Cl (I), (DCP)<sub>2</sub>CP (II), DPCP (III), DECP (IV), and (DMP)<sub>2</sub>CP (V) as a coupling agent, respectively.



**Figure 2.** Reversed-phase HPLC profiles of crude products of TpS<sub>2</sub>T preparations using the 5'-O-DMTr-thymidine *H*-phosphonothioate **3** on CPG **1** (R = DMTr) in the presence of (DMP)<sub>2</sub>CP as a coupling agent through treatment with 0.3 M solution of S<sub>8</sub> in 1:9 2,6-lutidine/pyridine for 15 min (I), 1 h (II), 4 h (III), and 8 h (IV), respectively.

electron-donating substituents on the phenyl groups, is likely to have enhanced the selectivity of *O*-activation (**4**) of *H*-phosphonothioate **3**. DECP, which possesses the electron-donating substituents in the ester moiety, also showed highly selective *O*-activation (**4**).


Investigations were then performed in an effort to ascertain the stability of phosphorodithioate under oxidation conditions. In the synthesis of oligonucleoside phosphonodithioates using *H*-phosphonothioates **3** (R = DMTr), significant amounts of desulfurized products were formed during oxidation using elemental sulfur following completion of *H*-phosphonothioate

oligomer assembly as reported by Caruthers and co-workers, although detailed data was not shown.<sup>7f</sup> We investigated the stability of TpS<sub>2</sub>T under oxidation conditions. Following *H*-phosphonothioate dimer **5** (B<sub>1</sub> = B<sub>2</sub> = T) assembly using (DMP)<sub>2</sub>CP as a coupling agent and subsequent removal of the DMTr group, oxidation was performed using elemental sulfur for either 15 min, 1, 4 or 8 h. TpS<sub>2</sub>T was cleaved from the support and subjected to analysis by reversed-phase HPLC. It was determined that sulfurization was complete within 15 min and that the amount of desulfurized products ([*Rp, Sp*]-TpST: [*Rp*]- and [*Sp*]-phosphorothioate dimers) increased slightly with increased time (Fig. 2).


Based on the studies described above, we extended our studies to the synthesis of long-chain oligonucleoside phosphonodithioates. Using the same procedure employed with DECP and (DMP)<sub>2</sub>CP as coupling agents through oxidation using elemental sulfur for 1 h at the end of the synthesis, oligomers [(TpS<sub>2</sub>)<sub>*n*</sub>T: trimer, tetramer, hexamer, and octamer] were assembled and HPLC tracings of each of the resulting mixtures are shown in Figure 3.<sup>15</sup> With (DMP)<sub>2</sub>CP as a coupling agent, the oligonucleoside phosphonodithioates were efficiently synthesized.

The phosphorodithioate oligomers were easily purified by reversed-phase HPLC, and the electrophoretic profiles gave clear single bands (Fig. 4). The structure of the products were consistent with data derived from <sup>31</sup>P NMR (Fig. 5) and ESI-TOF MS analyses.<sup>16</sup>


Synthesis of the phosphorodithioate octamer [(TpS<sub>2</sub>)<sub>7</sub>T] was accomplished by employing (DMP)<sub>2</sub>CP as a coupling



**Figure 3.** Reversed-phase HPLC profiles of crude products of phosphorodithioate oligomer [(TpS<sub>2</sub>)<sub>*n*</sub>T] preparations using the 5'-O-DMTr-thymidine 3'-phosphonothioate **3** on CPG **1** (R = DMTr) in the presence of DECP (I) and (DMP)<sub>2</sub>CP (II), respectively, through oxidation with S<sub>8</sub> for 1 h at the end of the synthesis. Conditions of reversed-phase HPLCs: column μ BONDASHERE 5 μ C18 (3.9 mm ID × 150 mm L); elution buffer 7.25–50% CH<sub>3</sub>CN/0.1 M TEAA (pH 7); flow rate 1 mL/min; detection UV at 260 nm.



**Figure 4.** Electrophoresis of the octamer [(TpS<sub>2</sub>)<sub>7</sub>T] on a 20% polyacrylamide gel containing 7 M urea, visualized by UV-shadowing.



**Figure 5.** <sup>31</sup>P NMR of the octamer [(TpS<sub>2</sub>)<sub>7</sub>T] in D<sub>2</sub>O.

agent in the synthetic cycles using the *H*-phosphonothioate method, and where oxidation using elemental sulfur was achieved following completion of oligonucleoside *H*-phosphonothioates assembly. Application of the approach detailed in this investigation will be useful in the synthesis of phosphorodithioate-type short oligonucleotides.

### Acknowledgements

The authors would like to thank Dr. Yasuo Shida for MS measurements (Analytical Center, Tokyo University of Pharmacy and Life Science).

### References and notes

- (a) Nielsen, J.; Brill, W. K.-D.; Caruthers, M. H. *Tetrahedron Lett.* **1988**, *29*, 2911–2914; (b) Grandas, A.; Marshall, W. S.; Nielsen, J.; Caruthers, M. H. *Tetrahedron Lett.* **1989**, *30*, 543–546; (c) Caruthers, M. H.; Beaton, G.; Cummins, L.; Dellinger, D.; Graff, D.; Ma, Y.-X.; Marshall, W. S.; Sasmor, H.; Shankland, P.; Wu, J. V.; Yan, E. K. *Nucleos. Nucleot.* **1991**, *10*, 47–59; (d) Beaton, G.; Brill, W. K.-D.; Grandas, A.; Ma, Y.-X.; Nielsen, J.; Yan, E.; Caruthers, M. H. *Tetrahedron* **1991**, *47*, 2377–2388; (e) Marshall, W. S.; Beaton, G.; Stein, C. A.; Matsukura, M.; Caruthers, M. H. *Proc. Natl. Acad. Sci. U.S.A.* **1992**, *89*, 6265–6269; (f) Marshall, W. S.; Caruthers, M. H. *Science* **1993**, *259*, 1564–1590.
- (a) Dahl, B. H.; Bjergarde, K.; Sommer, V. B.; Dahl, O. *Acta Chem. Scand.* **1989**, *43*, 896–901; (b) Dahl, B. H.; Bjergarde, K.; Nielsen, J.; Dahl, O. *Tetrahedron Lett.* **1990**, *31*, 3489–3492; (c) Bjergarde, K.; Dahl, O. *Nucleic Acids Res.* **1991**, *19*, 5843–5850.
- Porritt, G. M.; Reese, C. B. *Tetrahedron Lett.* **1989**, *30*, 4713–4716.
- Okruszek, A.; Sierzchala, A.; Feason, K. L.; Stec, W. J. *J. Org. Chem.* **1995**, *60*, 6998–7005.
- (a) Dahl, B. H.; Bjergarde, K.; Sommer, V. B.; Dahl, O. *Nucleos. Nucleot.* **1989**, *8*, 1023–1027; (b) Brill, W. K.-D.; Nielsen, J.; Caruthers, M. H. *J. Am. Chem. Soc.* **1991**, *113*, 3972–3980.
- (a) Brill, W. K.-D.; Nielsen, J.; Caruthers, M. H. *Tetrahedron Lett.* **1988**, *29*, 5517–5520; (b) Fraschtschi, N.; Gorenstein, D. G. *Tetrahedron Lett.* **1988**, *29*, 6843–6846; (c) Poggio, M. E.; Granger, J. N.; Cho, Y.; Fraschtschi, N.; Gorenstein, D. G. *Tetrahedron* **1991**, *47*, 2449–2461.
- (a) Stawinski, J.; Thelin, M.; Zain, R. *Tetrahedron Lett.* **1989**, *30*, 2157–2160; (b) Zain, R.; Stawinski, J. *J. Org. Chem.* **1996**, *61*, 6617–6622; (c) Dreef, K. E.; Dreef-Tromp, C. M.; van der Marel, G. A.; van Boom, J. H. *Synlett* **1990**, 481–483; (d) Wada, T.; Hata, T. *Tetrahedron Lett.* **1990**, *31*, 7461–7462; (e) Greef, C. H.; Seeberger, P. H.; Caruthers, M. H. *Tetrahedron Lett.* **1996**, *26*, 4451–4454; (f) Seeberger, P. H.; Caruthers, M. H. *Tetrahedron* **1999**, *55*, 5759–5772.
- (a) Brill, W. K.-D.; Yan, E. K.; Caruthers, M. H. *Tetrahedron Lett.* **1989**, *30*, 6621–6624; (b) Porritt, G. M.; Reese, C. B. *Tetrahedron Lett.* **1990**, *31*, 1319–1322; (c) Murata, T.; Iwai, S.; Ohtsuka, E. *Nucleic Acids Res.* **1990**, *18*, 7279–7286.
- Yau, E. K.; Ma, Y.-X.; Caruthers, M. H. *Tetrahedron Lett.* **1990**, *31*, 1953–1956.
- Okruszek, A.; Sierzchala, A.; Sochacki, M.; Stec, W. J. *Tetrahedron Lett.* **1992**, *33*, 7585–7588.
- Stawinski, J.; Thelin, M.; Westman, E.; Zain, R. *J. Org. Chem.* **1990**, *55*, 3503–3506.
- (a) Kamaike, K.; Takahashi, H.; Kakinuma, T.; Morohoshi, K.; Ishido, Y. *Tetrahedron Lett.* **1997**, *38*, 6857–6860; (b) Kamaike, K.; Takahashi, H.; Takahashi, H.; Morohoshi, K.; Kataoka, N.; Kakinuma, T.; Ishido, Y. *Acta Biochim. Pol.* **1998**, *45*, 949–976.
- Kamaike, K.; Hirose, K.; Kawashima, E. *Nucleic Acids Symp. Ser.* **2000**, *44*, 33–34.
- Seliger, H.; Scalfi, C.; Eisenbeiss, F. *Tetrahedron Lett.* **1983**, *24*, 4963–4966.
- Yield of  $\text{TpS}_2\text{T}$ : 11.9 (DECP) and 12.2 [(DMP) $_2$ CP]  $\text{A}_{260}$  units from **1** (R = DMTr, 1  $\mu\text{mol}$ ). Yield of  $(\text{TpS}_2)_2\text{T}$ : 11.8 (DECP) and 13.7 [(DMP) $_2$ CP]  $\text{A}_{260}$  units from **1** (R = DMTr, 1  $\mu\text{mol}$ ). Yield of  $(\text{TpS}_2)_3\text{T}$ : 9.5 (DECP) and 13.4 [(DMP) $_2$ CP]  $\text{A}_{260}$  units from **1** (R = DMTr, 1  $\mu\text{mol}$ ); Yield of  $(\text{TpS}_2)_5\text{T}$ : 11.6 [(DMP) $_2$ CP]  $\text{A}_{260}$  units from **1** (R = DMTr, 1  $\mu\text{mol}$ ); Yield of  $(\text{TpS}_2)_7\text{T}$ : 17.5 [(DMP) $_2$ CP]  $\text{A}_{260}$  units from **1** (R = DMTr, 1  $\mu\text{mol}$ ) (Fig. 3).
- $\text{TpS}_2\text{T}$ :  $^{31}\text{P}$  NMR ( $\text{D}_2\text{O}$ )  $\delta$  114.55 (s,  $\text{PS}_2$ , 1P); ESI-TOF MS  $m/z$  601 (M + Na) $^+$ .  $(\text{TpS}_2)_2\text{T}$ :  $^{31}\text{P}$  NMR ( $\text{D}_2\text{O}$ )  $\delta$  114.39 and 114.77 (2s,  $\text{PS}_2$ , 2P); ESI-TOF MS  $m/z$  937 (M + Na) $^+$ .  $(\text{TpS}_2)_3\text{T}$ :  $^{31}\text{P}$  NMR ( $\text{D}_2\text{O}$ )  $\delta$  114.38 (s,  $\text{PS}_2$ , 1P) and 114.59 (s,  $\text{PS}_2$ , 2P); ESI-TOF MS  $m/z$  1273 (M + Na) $^+$ .  $(\text{TpS}_2)_5\text{T}$ :  $^{31}\text{P}$  NMR ( $\text{D}_2\text{O}$ )  $\delta$  114.29, 114.32, 114.38, 114.40, and 114.46 (5s,  $\text{PS}_2$ , 5P); ESI-TOF MS  $m/z$  1945 (M + Na) $^+$ .  $(\text{TpS}_2)_7\text{T}$ :  $^{31}\text{P}$  NMR ( $\text{D}_2\text{O}$ )  $\delta$  114.26–114.44 (m,  $\text{PS}_2$ , 7P) (Fig. 4); ESI-TOF MS  $m/z$  2617 (M + Na) $^+$ .